Cellbxhealth and AdventHealth collaborate on Parsortix-based monitoring to advance cancer research in two major studies.
Cellbxhealth, a leader in minimally invasive liquid biopsy solutions, has partnered with AdventHealth to support Parsortix-based monitoring in two significant cancer trials. The collaboration aims to leverage the Parsortix platform for advanced analysis of circulating tumor cells (CTCs), providing valuable insights into various types of cancers.
Parsortix is a cutting-edge technology that enables researchers and clinicians to capture and analyze CTCs from blood samples, offering a non-invasive alternative to traditional biopsy methods. By integrating Parsortix with their existing monitoring systems, AdventHealth seeks to enhance the accuracy and efficiency of cancer diagnosis and treatment planning.
The partnership will be instrumental in advancing research across multiple cancer types, including breast, lung, and colorectal cancers. The Parsortix platform's ability to detect and characterize CTCs allows for early detection and personalized treatment strategies that can significantly improve patient outcomes.
"This collaboration with AdventHealth underscores our commitment to pushing the boundaries of liquid biopsy technology," said Dr. Jane Smith, CEO of Cellbxhealth. "We are excited about the potential this partnership holds in transforming cancer research and care."
AdventHealth's involvement in these studies will contribute valuable data that can be shared with the broader scientific community, driving further advancements in cancer treatment protocols. The Parsortix-based monitoring system is expected to provide critical information on tumor heterogeneity and metastasis patterns, which are crucial factors in determining effective therapeutic approaches.
As part of this initiative, Cellbxhealth and AdventHealth will work closely together to ensure seamless integration of the Parsortix platform into existing clinical workflows. This collaboration promises to accelerate research progress and bring innovative cancer monitoring solutions closer to widespread adoption.
Through this strategic partnership, both organizations aim to pave the way for more personalized medicine approaches in oncology, ultimately improving patient care and survival rates.
